Trial reportHaematologica2020
Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.
Abstract readClinical Trial, Phase IILetter
In one paragraph
Trial report in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Hemophagocytic lymphohistiocytosis associated with extranodal NK/T cell lymphoma, nasal type or aggressive NK cell leukemia: a retrospective multicenter study of Jiangsu Cooperative Lymphoma Group (JCLG).Annals of hematology · 2026Article
- Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.Therapeutic advances in medical oncology · 2026Article
- Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?Hematology. American Society of Hematology. Education Program · 2025Review
- The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.Blood advances · 2025Article
- Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH).Orphanet journal of rare diseases · 2025Review
- Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.BMC cancer · 2025Article
- Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting.Frontiers in oncology · 2025Review
- Advances in diagnosis and treatment of lymphoma-associated hemophagocytic syndrome.American journal of translational research · 2025Review
- The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients.Annals of hematology · 2024Article
- [Hemophagocytic syndrome secondary to invasive NK cell leukemia and T-cell lymphoma treated with the modified MINE protocol: report of three cases and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Article
- The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.Journal of clinical immunology · 2023Article
- Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2023Article
- Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.Frontiers in immunology · 2022Article
- [Research progress of lymphoma associated hemophagocytic syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Jin-Hua LiangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Li WangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Hua-Yuan ZhuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Jun QianDepartment of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu.
Hui LiaoDepartment of Hematology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.
Jia-Zhu WuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Yi XiaDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Wei WuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Lei CaoDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Lei FanDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing.
Jian-Yong LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing lijianyonglm@126.com.
Wei XuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing xuwei10000@hotmail.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphohistiocytosis, HemophagocyticLymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinEtoposideHumansPrednisoneVincristineCyclophosphamideDoxorubicinEtoposidePrednisoneVincristine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.